Literature DB >> 31594763

The impact of response kinetics for multiple myeloma in the era of novel agents.

Yuting Yan1, Xuehan Mao1, Jiahui Liu1, Huishou Fan1, Chenxing Du1, Zengjun Li1, Shuhua Yi1, Yan Xu1, Rui Lv1, Wei Liu1, Shuhui Deng1, Weiwei Sui1, Qi Wang1, Dehui Zou1, Jianxiang Wang1, Tao Cheng1, Fenghuang Zhan2, Yu-Tzu Tai3, Chenglu Yuan4, Xin Du5, Lugui Qiu1, Kenneth C Anderson3, Gang An1,4,5.   

Abstract

Rapid remission by induction therapy has long been recognized as an important predictor for long-time survival in acute leukemia. However, the impact of response kinetics on multiple myeloma (MM) seems to be different and remains unexplored. The relationship between response kinetics and outcome were assessed in 626 patients with newly diagnosed MM who were included in a prospective, nonrandomized clinical trial (BDH 2008/02). Patients were assigned to either immunomodulatory drug- or proteasome inhibitor-based therapy. The response depth, time to best response (TBR) and duration of best response (DBR) were collected. Depth of response was associated with superior outcomes, consistent with findings from other studies. However, the early responders (defined as TBR ≤3 months) showed significantly worse survival compared with late responders. We found that patients with rapid complete remission experienced inferior survivals comparable to those attaining a gradual partial remission. Moreover, 4 distinct response kinetics patterns were identified. Patients with gradual and sustained remission ("U-valley" pattern) experienced superior outcomes, whereas poor outcomes were observed in rapid and transient responders ("roller coaster" pattern) (median overall survival, 126 vs 30 months). The effects of response patterns on survival were confirmed in patients at different stages of disease and cytogenetic risk, including transplant-eligible patients and those attaining different extents of response depth. Collectively, our data indicated that slow and gradual response is a favorable prognostic factor in MM. In addition to response depth, the kinetic pattern of response is a simple and powerful predictor for survival even in the era of novel agents.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31594763      PMCID: PMC6784522          DOI: 10.1182/bloodadvances.2019000432

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  34 in total

1.  Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

Authors:  Gang An; Yan Xu; Lihui Shi; Zhong Shizhen; Shuhui Deng; Zhenqing Xie; Weiwei Sui; Fenghuang Zhan; Lugui Qiu
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

2.  Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma.

Authors:  Moritz Binder; S Vincent Rajkumar; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Francis K Buadi; David Dingli; Suzanne R Hayman; John A Lust; Prashant Kapoor; Yi Lin; Ronald S Go; Yi L Hwa; Robert A Kyle; Shaji K Kumar
Journal:  Am J Hematol       Date:  2015-09-01       Impact factor: 10.047

3.  Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Authors:  Surbhi Sidana; Nidhi Tandon; Angela Dispenzieri; Morie A Gertz; Francis K Buadi; Martha Q Lacy; David Dingli; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Rahma M Warsame; Taxiarchis Kourelis; Yi Lisa Hwa; Prashant Kapoor; Robert A Kyle; Nelson Leung; Ronald S Go; S Vincent Rajkumar; Shaji K Kumar
Journal:  Leukemia       Date:  2018-10-15       Impact factor: 11.528

4.  The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.

Authors:  Gang An; Zengjun Li; Yu-Tzu Tai; Chirag Acharya; Qian Li; Xiaoqi Qin; Shuhua Yi; Yan Xu; Xiaoyan Feng; Chengwen Li; Jiawei Zhao; Lihui Shi; Meirong Zang; Shuhui Deng; Weiwei Sui; Mu Hao; Dehui Zou; Yaozhong Zhao; Junyuan Qi; Tao Cheng; Kun Ru; Jianxiang Wang; Kenneth C Anderson; Lugui Qiu
Journal:  Clin Cancer Res       Date:  2015-02-04       Impact factor: 12.531

5.  MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.

Authors:  Hong-Hu Zhu; Xiao-Hui Zhang; Ya-Zhen Qin; Dai-Hong Liu; Hao Jiang; Huan Chen; Qian Jiang; Lan-Ping Xu; Jin Lu; Wei Han; Li Bao; Yu Wang; Yu-Hong Chen; Jing-Zhi Wang; Feng-Rong Wang; Yue-Yun Lai; Jun-Yue Chai; Li-Ru Wang; Yan-Rong Liu; Kai-Yan Liu; Bin Jiang; Xiao-Jun Huang
Journal:  Blood       Date:  2013-03-27       Impact factor: 22.113

6.  Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Authors:  Jin Seok Kim; Kihyun Kim; June-Won Cheong; Yoo Hong Min; Cheolwon Suh; Hawk Kim; Deog Yeon Jo; Hun Mo Ryoo; Sung Soo Yoon; Jae Hoon Lee
Journal:  Biol Blood Marrow Transplant       Date:  2009-04       Impact factor: 5.742

7.  Early response to therapy and survival in multiple myeloma.

Authors:  C G Schaar; J C Kluin-Nelemans; S le Cessie; P F H Franck; M C te Marvelde; P W Wijermans
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

8.  Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.

Authors:  Bart Barlogie; Elias Anaissie; Jeffrey Haessler; Fritz van Rhee; Mauricio Pineda-Roman; Klaus Hollmig; Yazan Alsayed; Joshua Epstein; John D Shaughnessy; John Crowley
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

9.  High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

Authors:  Frits van Rhee; Vanessa Bolejack; Klaus Hollmig; Mauricio Pineda-Roman; Elias Anaissie; Joshua Epstein; John D Shaughnessy; Maurizio Zangari; Guido Tricot; Abid Mohiuddin; Yazan Alsayed; Gail Woods; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2007-04-06       Impact factor: 22.113

10.  Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

Authors:  N Majithia; S V Rajkumar; M Q Lacy; F K Buadi; A Dispenzieri; M A Gertz; S R Hayman; D Dingli; P Kapoor; L Hwa; J A Lust; S J Russell; R S Go; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

View more
  11 in total

1.  The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors:  Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Adv       Date:  2020-09-08

2.  Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation.

Authors:  Kewa Ma; Jiannan Ye; Lingling Wang; Chao Sun; Xin Zhou
Journal:  Onco Targets Ther       Date:  2021-04-06       Impact factor: 4.147

3.  Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

Authors:  Liang Lin; Shih-Feng Cho; Lijie Xing; Kenneth Wen; Yuyin Li; Tengteng Yu; Phillip A Hsieh; Hailin Chen; Metin Kurtoglu; Yi Zhang; C Andrew Stewart; Nikhil Munshi; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Leukemia       Date:  2020-07-06       Impact factor: 11.528

4.  Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.

Authors:  Rafael Alonso; Juan José Lahuerta
Journal:  Front Oncol       Date:  2022-01-14       Impact factor: 6.244

5.  [Clinical analysis of 25 patients with non transplanted multiple myeloma who survived for more than 10 years].

Authors:  M Shen; X Li; G Z Yang; J J Zhang; R Tang; Z X Huang; W M Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-02-14

6.  Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.

Authors:  Haiyan He; Zifeng Li; Jing Lu; Wanting Qiang; Sihan Jiang; Yaochen Xu; Weijun Fu; Xiaowen Zhai; Lin Zhou; Maoxiang Qian; Juan Du
Journal:  Clin Transl Med       Date:  2022-03

7.  Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.

Authors:  Meera Mohan; Samantha Kendrick; Aniko Szabo; Naveen Yarlagadda; Dinesh Atwal; Yadav Pandey; Arya Roy; Richa Parikh; James Lopez; Sharmilan Thanendrarajan; Carolina Schinke; Daisy Alapat; Jeffrey Sawyer; Erming Tian; Guido Tricot; Frits van Rhee; Maurizio Zangari
Journal:  Blood Adv       Date:  2022-02-08

8.  Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.

Authors:  Alexander Schmitz; Rasmus Froberg Brøndum; Hans Erik Johnsen; Ulf-Henrik Mellqvist; Anders Waage; Peter Gimsing; Davine Hofste Op Bruinink; Vincent van der Velden; Bronno van der Holt; Markus Hansson; Niels Frost Andersen; Ulf Christian Frølund; Carsten Helleberg; Fredrik H Schjesvold; Lucia Ahlberg; Nina Gulbrandsen; Bjorn Andreasson; Birgitta Lauri; Einar Haukas; Julie Støve Bødker; Anne Stidsholt Roug; Martin Bøgsted; Marianne T Severinsen; Henrik Gregersen; Niels Abildgaard; Pieter Sonneveld; Karen Dybkær
Journal:  BMC Cancer       Date:  2022-02-05       Impact factor: 4.430

9.  Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

Authors:  Sriram Ravichandran; Oliver C Cohen; Steven Law; Darren Foard; Marianna Fontana; Ana Martinez-Naharro; Carol Whelan; Julian D Gillmore; Helen J Lachmann; Sajitha Sachchithanantham; Shameem Mahmood; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood Cancer J       Date:  2021-06-21       Impact factor: 11.037

10.  Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.

Authors:  Yael C Cohen; Mor Zada; Shuang-Yin Wang; Chamutal Bornstein; Eyal David; Adi Moshe; Baoguo Li; Shir Shlomi-Loubaton; Moshe E Gatt; Chamutal Gur; Noa Lavi; Chezi Ganzel; Efrat Luttwak; Evgeni Chubar; Ory Rouvio; Iuliana Vaxman; Oren Pasvolsky; Mouna Ballan; Tamar Tadmor; Anatoly Nemets; Osnat Jarchowcky-Dolberg; Olga Shvetz; Meirav Laiba; Ofer Shpilberg; Najib Dally; Irit Avivi; Assaf Weiner; Ido Amit
Journal:  Nat Med       Date:  2021-02-22       Impact factor: 87.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.